The Epidemiology of the Weiss Cohort Project

Weiss 队列项目的流行病学

• 批准号: 10227898
• 负责人: Stanley H Weiss
• 金额: $ 77.25万
• 依托单位: RBHS-NEW JERSEY MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-15 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10227898
• 关键词: AIDS/HIV problem; ATOD; Accounting; African American; Age; Aging; Agreement; Applications Grants; Authorization documentation; Back; Behavioral; Biological Specimen Banks; Biotechnology; Blood; Caring; Cause of Death; Cessation of life; Cholangiocarcinoma; Chronic; Cohort Studies; Data; Data Set; Death Certificates; Disease; Disease Outcome; Drug Interactions; Drug abuse; Drug usage; Drug user; Enrollment; Epidemic; Epidemiology; Ethnic Origin; European; Evolution; Exposure to; Female; Future; Gender; Genetic; Geography; Goals; Grant; HIV; HIV Seronegativity; HIV risk; Health; Health system plans; Hepatitis C; Hepatitis C virus; Highly Active Antiretroviral Therapy; Hispanics; Human immunodeficiency virus test; Incidence; Individual; Infection; Infectious Agent; Institutes; Intervention; Laboratories; Link; Liver Failure; Liver diseases; Longitudinal Studies; Longitudinal cohort; Longterm Follow-up; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of lung; Medical; Minority Groups; National Cancer Institute; National Institute of Drug Abuse; Opioid; Outcome; Outcome Assessment; Participant; Pattern; Persons; Pharmaceutical Preparations; Policies; Population; Prevention; Prospective cohort; Race; Recording of previous events; Registries; Relative Risks; Resources; Risk; Risk Factors; Series; Smoking; Source; Stage at Diagnosis; Survival Analysis; Survivors; Time; Treatment Protocols; Underrepresented Minority; Vital Statistics; Woman; Work; adjudicate; burden of illness; cancer epidemiology; cancer risk; cancer site; clinical epidemiology; clinical practice; cohort; data registry; disorder risk; follow-up; high risk; indexing; male; mortality; neoplasm registry; public health intervention; recruit; sex; tool; treatment program

PROJECT SUMMARY/ABSTRACT The goals of this project are to further our understanding of the long-term clinical epidemiology of health outcomes among drug users who are at high risk for HIV. This is important because it will guide clinical practice and health systems planning in the face of the continuing HIV/AIDS epidemic and the evolving epidemic of drug abuse, including opioids. Many HIV-infected persons are living longer than they had in the past, due to the advent and availability of highly active antiretroviral therapy. We have a unique prospective cohort of drug users established in the 1980s, backed by a linked biospecimen repository and permission for indefinite continuing follow-up, established by the NCI and NIDA for the long- term study of drug users. The cohort numbers nearly 11,000 drug users, who are diverse in gender, race, ethnicity and geography, and include large numbers of both HIV-positive and HIV-negative persons. Hepatitis C virus infection is extremely common in these persons. WE SEEK TO UNDERSTAND THE HEALTH OUTCOMES IN THIS COHORT THROUGH TWO AIMS. AIM 1. To determine the epidemiologic features of mortality outcomes associated with HIV among drug users over a 35-year period. This will be accomplished by matching our cohort to vital statistics registry data. AIM 2. To determine the cancer epidemiology, by cancer site, among drug users over a 35-year period, including incidence, stage at diagnosis, treatment regimens, mortality, and HIV-associated risk. This will be accomplished by matching our cohort to cancer registry data. Our project analyses will integrate these two types of data, with stepwise repetition of matching over several years. Mortality data will enable us to more accurately conduct survival analyses on an array of disease outcomes, with a special focus on cancer to identify putative risk factors. This has the potential to assist with the identification of interventions that would reduce disease burden and prolong survival. We will characterize disease outcomes in HIV-positive compared to HIV-negative drug users, accounting for baseline demographic, behavioral, and medical factors. Our cohort uniquely affords the opportunity to study health outcomes over a prolonged time period spanning several decades in both sexes and in underrepresented minority populations. The size of our study and the extent and richness of baseline data will make it a powerful tool in understanding a wide array of disease outcomes. Given the continuing rapid evolution of biotechnology, future research might employ evolving biotechnology to use our biospecimen repository to explore specific disease outcomes we will be identifying. Our cohort has joined the NIDA Genetics Consortium. We will explore joining other consortia which focus on other outcomes, which could amplify the power of those consortia.

项目摘要/摘要 该项目的目标是进一步了解我们对健康的长期临床流行病学 艾滋病毒高风险的吸毒者的结果。这很重要，因为它将指导临床 面对持续的艾滋病毒/艾滋病流行和不断发展的练习和卫生系统计划 药物滥用的流行，包括阿片类药物。许多艾滋病毒感染者的寿命比在 过去，由于高度活跃的抗逆转录病毒疗法的出现和可用性。 我们拥有1980年代建立的独特的吸毒者队列，并得到链接的生物测试 由NCI和NIDA建立的存储库和允许无限期的持续后续行动 吸毒者的学期研究。该队列人数近11,000名吸毒者，他们的性别，种族，种族多样 种族和地理，包括大量的HIV阳性和HIV阴性人。肝炎 C病毒感染在这些人中非常普遍。 我们试图通过两个目标来了解该队列中的健康成果。 目的1。确定吸毒者中与HIV相关的死亡率结果的流行病学特征 在35年的时间内。这将通过将我们的队列与重要统计注册表数据匹配来实现。 目的2。确定癌症的癌症流行病学，在35年内吸毒者中的癌症患者， 包括发病率，诊断阶段，治疗方案，死亡率和与HIV相关的风险。这将是 通过将我们的队列与癌症注册表数据相匹配来完成。 我们的项目分析将整合这两种类型的数据，并逐步重复匹配。 年。死亡率数据将使我们能够更准确地对一系列疾病进行生存分析 结果，特别关注癌症以识别推定的危险因素。这有可能协助 鉴定会减轻疾病负担并延长生存的干预措施。 与HIV阴性药物使用者相比 基线人口统计，行为和医学因素。我们的队列独特地提供了学习的机会 长期延长的健康状况在性别和男女中都有数十年 代表性不足的少数民族人口。 我们的研究规模以及基线数据的程度和丰富性将使它成为理解的强大工具 各种各样的疾病结果。鉴于生物技术的持续快速发展，未来的研究可能 利用不断发展的生物技术利用我们的生物测量存储库来探索特定的疾病结果，我们将 识别。我们的队列加入了NIDA遗传学联盟。我们将探索加入其他财团 这关注其他结果，这可能会扩大这些财团的力量。